Aura Biosciences Announces 2024 Annual Meeting of Stockholders on June 20, 2024

TL;DR

<b>Aura Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors, approve charter amendments, and ratify auditors.</b>

AI Summary

Aura Biosciences, Inc. (AURA) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Aura Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 9:30 a.m. Eastern Time. The meeting agenda includes the election of two Class III directors, approval of an amendment to the Certificate of Incorporation regarding officer exculpation, and ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024. Stockholders of record as of April 22, 2024, are entitled to vote at the meeting. Proxy materials are being furnished to stockholders via the Internet under the SEC's 'Notice and Access' rule. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

For investors and stakeholders tracking Aura Biosciences, Inc., this filing contains several important signals. The virtual format and 'Notice and Access' rule for proxy materials indicate a move towards digital shareholder engagement and cost-efficiency in communication. Key proposals include director elections and a corporate governance amendment concerning officer exculpation, which are standard but important for board composition and liability protection.

Risk Assessment

Risk Level: low — Aura Biosciences, Inc. shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) with no immediate financial or operational news, indicating low risk.

Analyst Insight

Stockholders should review the proxy materials to understand the director nominees and the proposed charter amendment before the June 20, 2024 meeting.

Key Numbers

• 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
• June 20 — Meeting Date (Annual Meeting date)
• 9:30 a.m. Eastern Time — Meeting Time (Annual Meeting time)
• April 22, 2024 — Record Date (Stockholders of record date)
• Two — Directors to be Elected (Election of two Class III directors)
• 2027 — Director Term End (Serve until the 2027 annual meeting)
• 2024 — Fiscal Year End (Fiscal year ending December 31, 2024)

Key Players & Entities

• Aura Biosciences, Inc. (company) — Registrant
• Ernst & Young LLP (company) — independent registered public accounting firm
• June 20, 2024 (date) — Annual Meeting date
• April 22, 2024 (date) — Record date for voting
• Boston, MA (location) — Company address

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
• Virtual Meeting Logistics [low — operational]: Ensuring a smooth virtual meeting experience for all stockholders, including technical support and question submission.
• Independent Auditor Ratification [low — financial]: Stockholder approval of the independent auditor is crucial for financial reporting integrity.
• Officer Exculpation Amendment [low — legal]: Approval of the amendment to the Certificate of Incorporation regarding exculpation of officers impacts potential director and officer liability.

Key Dates

• 2024-04-22: Record Date — Determines which stockholders are eligible to vote at the annual meeting.

Key Financial Figures

• $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
• $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
• $0.00001 — 8 shares of our common stock, par value $0.00001 per share, outstanding on April 22, 202

Filing Documents

• d509116ddef14a.htm (DEF 14A) — 409KB
• g509116g0412212744572.jpg (GRAPHIC) — 3KB
• g509116page45.jpg (GRAPHIC) — 8KB
• g509116page45a.jpg (GRAPHIC) — 8KB
• 0001193125-24-113878.txt (&nbsp;) — 437KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 26 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 32 PRINCIPAL STOCKHOLDERS 34 REPORT OF THE AUDIT COMMITTEE 37 HOUSEHOLDING 38 STOCKHOLDER PROPOSALS 38 OTHER MATTERS 38 APPENDIX A 39 i Table of Contents AURA BIOSCIENCES, INC. 80 Guest Street Boston, MA 02135 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 20, 2024 This proxy statement contains information about the 2024 Annual Meeting of Stockholders, or the Annual Meeting, of Aura Biosciences, Inc., which will be held online on June 20, 2024 at 9:30 a.m. Eastern Time. This years Annual Meeting will be held virtually. You may attend the Annual Meeting virtually via the Internet at www.virtualshareholdermeeting.com/AURA2024, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials, or Notice, or proxy card being mailed to you separately in order to attend the Annual Meeting. The board of directors of Aura Biosciences, Inc., or the Board of Directors, is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms Aura, Aura Biosciences, the Company, we, us, and our refer to Aura Biosciences, Inc. The mailing address of our principal executive offices is Aura Biosciences, Inc., 80 Guest Street, Boston, MA 02135. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our Board of Directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting by giving our Corporate Secretary written notice to that effect. This proxy statement and our 2023 Annual Report to Stockholde

: Gender Identity

Part I: Gender Identity Directors 2 4 1

: Demographic Background

Part II: Demographic Background African American or Black Alaskan N